NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) (“NervGen” or the “Company”), a clinical-stage biopharmaceutical company ...
The Form 40-F filing is an important step in the Company's U.S. growth strategy. Subject to SEC effectiveness and Nasdaq approval, the Nasdaq listing would expand F3's presence in the U.S. capital ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback